Answers are grounded in this paper and cite their sources.
Case report demonstrates long-term chylothorax post-dasatinib in a CML patient, suggesting conservative treatment options.
Tyrosine kinase inhibitors (TKIs) are used to treat patients with chronic myelogenous leukemia (CML), leading to a nearly normal life expectancy. Sprycel (dasatinib)–induced chylothorax has rarely been reported in patients undergoing CML treatment. We report a 10-year case history of chronic chylothorax that persisted despite discontinuation of dasatinib in a patient with otherwise excellent results after switching to another TKI. Herein, we discuss a conservative treatment approach that uses symptom-based thoracentesis instead of surgical ligation of the thoracic duct. This approach may reduce patient morbidity and prevent the need for complex surgical procedures. TKIs have revolutionized CML treatment; however, these powerful medications are not without patient morbidity.
No takes yet. Share an insight, caveat, or question.
Thaker et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: